Artivion, Inc.
Artivion, Inc. (AORT) Insider Trading
Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.
SEC EDGAR · FMP · AORT · as of Jun 8, 2026
Activity summary
Buy transactions
0
P-Purchase only
Sell transactions
62
12 Months
Buy/Sell ratio
0.00
Buy/Sell (by trades)
Overall sentiment
Artivion, Inc. insiders have been primarily selling shares over the past 12 Months. Selling activity is often driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment toward the company.
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only
As of Jun 8, 2026
AORT insider buying and selling by quarter
AORT insider selling · AORT insider buying stocks · quarterly insider activity
Mobile shows last 4Q · Desktop shows full 8Q
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters
As of Jun 8, 2026
Active insiders
Most active in past 12 months · AORT ceo insider trading
Showing all insiders · Click a card to filter the transactions table below
▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API
Recent insider transactions
AORT executive sell shares · AORT board member insider trading · AORT insider trading SEC filing
Scroll horizontally to see all columns
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| Jun 2, 2026 | SEMEDO ANTHONY B. Director | Other | 6,325 | — | Form 4 |
| Jun 2, 2026 | SEMEDO ANTHONY B. Director | Other | 6,325 | — | Form 4 |
| May 18, 2026 | SEMEDO ANTHONY B. Director | Award | 7,576 | — | Form 4 |
| May 18, 2026 | Salveson Jon W Director | Award | 7,576 | — | Form 4 |
| May 18, 2026 | Hoff Elizabeth A Director | Award | 7,576 | — | Form 4 |
| May 18, 2026 | Burbank Jeffrey H Director | Award | 7,576 | — | Form 4 |
| May 18, 2026 | Bullock James Director | Award | 7,576 | — | Form 4 |
| May 18, 2026 | BEVEVINO DANIEL J Director | Award | 7,576 | — | Form 4 |
| May 18, 2026 | ACKERMAN THOMAS F Director | Award | 7,576 | — | Form 4 |
| May 14, 2026 | Borgstrom Marna P Director | Award | 7,850 | — | Form 4 |
| Mar 2, 2026 | Horton Amy VP, Chief Accounting Officer | Award | 7,475 | — | Form 4 |
| Mar 3, 2026 | Horton Amy VP, Chief Accounting Officer | Sale | 901 | $34K | Form 4 |
| Mar 2, 2026 | Holloway Jean F SVP, General Counsel | Award | 27,795 | — | Form 4 |
| Mar 3, 2026 | Holloway Jean F SVP, General Counsel | Sale | 3,843 | $145K | Form 4 |
| Mar 4, 2026 | Holloway Jean F SVP, General Counsel | Sale | 8,962 | $341K | Form 4 |
| Mar 2, 2026 | Stanton Marshall S. SVP, Clinical & MD Affair | Award | 21,838 | — | Form 4 |
| Mar 3, 2026 | Stanton Marshall S. SVP, Clinical & MD Affair | Sale | 2,149 | $81K | Form 4 |
| Mar 2, 2026 | Davis John E Chief Commercial Officer | Award | 28,845 | — | Form 4 |
| Mar 3, 2026 | Davis John E Chief Commercial Officer | Sale | 4,573 | $173K | Form 4 |
| Mar 2, 2026 | Berry Lance A EVP, COO, CFO & Treasurer | Award | 40,874 | — | Form 4 |
| Mar 3, 2026 | Berry Lance A EVP, COO, CFO & Treasurer | Sale | 6,316 | $239K | Form 4 |
| Mar 2, 2026 | Mackin James P President & CEO | Award | 116,948 | — | Form 4 |
| Mar 3, 2026 | Mackin James P President & CEO | Sale | 17,887 | $676K | Form 4 |
| Mar 2, 2026 | Horton Amy VP, Chief Accounting Officer | Sale | 641 | $24K | Form 4 |
| Mar 2, 2026 | Stanton Marshall S. SVP, Clinical & MD Affair | Sale | 1,513 | $58K | Form 4 |
Horton Amy
VP, Chief Accounting Officer
Date
Mar 3
Shares
901
Price
$37.78
Value
$34K
Holloway Jean F
SVP, General Counsel
Date
Mar 3
Shares
3,843
Price
$37.78
Value
$145K
Holloway Jean F
SVP, General Counsel
Date
Mar 4
Shares
8,962
Price
$38.00
Value
$341K
Stanton Marshall S.
SVP, Clinical & MD Affair
Date
Mar 2
Shares
21,838
Price
—
Value
—
Stanton Marshall S.
SVP, Clinical & MD Affair
Date
Mar 3
Shares
2,149
Price
$37.78
Value
$81K
Davis John E
Chief Commercial Officer
Date
Mar 3
Shares
4,573
Price
$37.78
Value
$173K
Berry Lance A
EVP, COO, CFO & Treasurer
Date
Mar 3
Shares
6,316
Price
$37.78
Value
$239K
Horton Amy
VP, Chief Accounting Officer
Date
Mar 2
Shares
641
Price
$38.02
Value
$24K
Stanton Marshall S.
SVP, Clinical & MD Affair
Date
Mar 2
Shares
1,513
Price
$38.02
Value
$58K
⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar
▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —
About AORT insider trading
AORT insider trades
Artivion, Inc. (AORT) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including Holloway Jean F (SVP, General Counsel), Stanton Marshall S. (SVP, Clinical & MD Affair), Davis John E (Chief Commercial Officer). Over the past 12 months, 5 insiders have filed transactions with the SEC. AORT insiders have been primarily selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.
For Artivion, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →
Frequently asked questions
AORT insider trading · 5 questionsThe insiders of Artivion, Inc. (AORT) include executives and directors such as Holloway Jean F (SVP, General Counsel), Stanton Marshall S. (SVP, Clinical & MD Affair), Davis John E (Chief Commercial Officer), among others. Over the past 12 months, 5 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.
▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 8, 2026